Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.
FAQs
Codex DNA (DNAY) Stock Forecast, Price Targets and Analysts Predictions - TipRanks.com? ›
The average price target is $5.00 with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 284.62% change from the last price of $1.30.
What is Ginkgo Bioworks stock prediction for 2024? ›According to our current DNA stock forecast, the value of Ginkgo Bioworks Holdings, Inc. shares will rise by 11.89% and reach $ 0.457298 per share by June 26, 2024. Per our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).
What is the prediction for DNA stock? ›According to analysts, DNA price target is 1.22 USD with a max estimate of 3.00 USD and a min estimate of 0.50 USD.
Is DNA stock a buy or sell? ›DNA Stock Forecast FAQ
Ginkgo Bioworks Holdings has 71.23% upside potential, based on the analysts' average price target. Ginkgo Bioworks Holdings has a consensus rating of Moderate Sell which is based on 0 buy ratings, 1 hold ratings and 3 sell ratings. The average price target for Ginkgo Bioworks Holdings is $0.77.
For now, investors are better off staying away from the stock as there's still far too much risk with Ginkgo and, despite its struggles, it can still go much lower given its fairly high $1.8 billion valuation. There are much better growth stocks out there for investors to pursue than Ginkgo.
Is Bill Gates invested in Ginkgo Bioworks? ›Bill Gates angel profile
Has made 69 investments including Wagestream, Ginkgo Bioworks. Investor has 10 Exits and 4 Unicorns.
Ginkgo Bioworks (DNA -2.83%) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst Mark Massaro downgraded Ginkgo stock to sell, and lowered his price on this biotech penny stock to just $0.50.
Does Cathie Wood own DNA stock? ›Ginkgo Bioworks
29 alone, Cathie Wood has been an enthusiastic buyer of shares in Ginkgo Bioworks Holdings (NYSE: DNA). It's no surprise what might draw her to this company as it stands to disrupt major biopharmaceutical manufacturing processes.
Based on short-term price targets offered by six analysts, the average price target for Ginkgo Bioworks Holdings, Inc. comes to $1.48. The forecasts range from a low of $0.50 to a high of $3.00.
Why is Ginkgo Bioworks being sued? ›According to the complaint, Defendants made false and/or misleading statements and failed to disclose that: (1) the Company's failure to derive real revenue from third-party customers left it almost completely dependent on related parties; (2) most, if not all, of the Company's revenue came from related parties the ...